Phase 3 Readout

IVA: Phase 3 Topline: A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase 3 Study Evaluating Efficacy and S

Name: Phase 3 Topline: A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase 3 Study Evaluating Efficacy and S
Start: 2027-09-30
End: 2027-09-30

September 30, 2027. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: September 30, 2027
Company: Inventiva S.A. (IVA)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase 3 Study Evaluating Efficacy and S

September 30, 2027

IVA overview →

Company: Inventiva S.A. (IVA)
Indication: NASH - Nonalcoholic Steatohepatitis